Skip to main content
. 2016 Aug 23;33(2):111–116. doi: 10.1016/j.joa.2016.07.008

Table 1.

Background characteristics of the subjects enrolled in ASSAF-K.

Parameter Total (N=3847)
Age 72.9±10.1
Male:Female 2512:1335
Body mass index, kg/m² 23.4±3.6
SBP/DBP (mmHg) 126.5±16.3/
73.1±11.5
PR (bpm) 74.5±18.8
Cr (mg/dL) 1.08±1.17
CCr 66.6±28.6
eGFR 59.6±19.5
Clinical Score
CHADS2 Score 1.81±1.27
CHADS2 Vasc Score 3.02±1.58
HAS BLED Score 2.23±1.06
Concomitant diseases
CHF 22.90%
Hypertension 60.10%
Diabetes Mellitus 20.20%
Cerebral Infarction 13.70%
Cerebral Hemorrhage 0.90%
TIA 2.10%
OMI 5.90%
Angina pectoris 9.00%
PAD 2.30%
HCM 1.70%
DCM 2.10%
Liver Dysfunction 1.40%
Hemorrhagic Disease 1.10%
Hemodyalisis 1.50%
Neoplasm 4.30%
Thyroid Dysfunction 3.00%
Interventional procedures
PCI 10.70%
Catheter Ablation 5.80%
Maze Operation 0.50%
DC 1.00%
Pharmacological Defibrillation 0.20%
Concomitant structural heart diseases
Mitral Stenosis 1.90%
Mitral Regurgitation 14.10%
Mechanical Valve Replacement 1.90%
Biological Valve Replacement 0.50%
Other Valvular Disease 5.50%
Medications
Digitalis 15.90%
β-blockade 32.90%
Calcium Channel Blockade 11.50%
Other Anti-arrhythmic Drugs 16.20%
Anti-platelet medications
ASA 18.50%
Ticlopidine 1.10%
Clopidogrel 3.70%
Cilostazol 1.20%
Anti-coagulant medications
Warfarin 44.20%
All NOAC 33.50%
Dabigatran 15.00%
Ribaroxaban 15.00%
Apixaban 3.50%
Edoxaban 0.02%

Abbreviations: ASA, acetylsalicylic acid; Cr, creatinine; CCr, creatinine clearance; CHF, chronic heart failure; DC, direct current defibrillation; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; HCM, hypertrophic cardiomyopathy; NOAC, new oral anticoagulant; OMI, old myocardial infarction; PAD, peripheral aretery disease; PCI, percutaneous coronary intervention; PR, pulse rate; SBP/DBP, systolic blood pressure/diastolic blood pressure; TIA, transient ischemic attack